Matica Biotech and KaliVir Ink LOI for Oncolytic Viral Immunotherapy Ties

Matica Biotechnology Inc. (Matica Bio), a company specializing in viral vector development and manufacturing, has revealed the signing of a Letter of Intent (LOI) with KaliVir Immunotherapeutics, a clinical-stage biotechnology company from the U.S. working on advanced, multi-mechanistic oncolytic viral immunotherapies.

KaliVir is leading the way in creating new cancer treatments with their exclusive Vaccinia Enhanced Template (VET™) platform. This platform enables the expression and systematic delivery of numerous therapeutic transgenes. The primary clinical candidate of KaliVir, VET3-TGI, produces interleukin-12 and a TGFbeta inhibitor.

In this new collaboration, Matica Bio will use their exclusive cell line, MatiMax™, to investigate a different production method for KaliVir’s oncolytic virus product.

Helena Chaye, CEO of KaliVir, stated, “Our collaboration with Matica Bio allows us to accelerate the development of our oncolytic virus therapies. This agreement is expected to expand our strategic partnership across all phases of product development.”

“The development of production processes for viral vectors is crucial for the stable production of high-quality therapeutics. Through this agreement, we aim to leverage our high-performance MatiMax™ cell line and CGT manufacturing expertise to actively support KaliVir’s oncolytic virus program,” said Paul Kim, CEO of Matica Bio.

Matica Biotechnology is a CDMO specializing in viral vector manufacturing that utilizes cutting-edge technologies at its dedicated cGMP facility.